ScholarWorks@Hanyang University: Bae, Sang Cheol

Detailed Information

Bae, Sang Cheol (배상철)

COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 의학, 내과학, Medicine, Internal Medicine

Tel 02-2290-9237
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Rheumatoid arthritis:92||Polymorphism:42||systemic lupus erythematosus:41||rheumatoid arthritis:39||Metaanalysis:38||Systemic lupus erythematosus:37||polymorphism:30||Autoimmune diseases:19||metaanalysis:18||SLE:13||Safety:12||systemic:11||lupus erythematosus:10||epidemiology:9||rheumatoid:9||RHEUMATOID ARTHRITIS:8||Arthritis:8||Efficacy:7||Inflammation:7||Systemic Lupus Erythematosus:7||genetic:7||Etanercept:7||Network metaanalysis:7||arthritis:6||SYSTEMIC LUPUS ERYTHEMATOSUS:6||Cyclophosphamide:6||Epidemiology:6||Lupus nephritis:6||TNF inhibitor:6||Korea:6||Mendelian randomization:6||Prevalence:6||autoimmunity:6||Ankylosing spondylitis:6||Rheumatoid:5||autoimmune diseases:5||Disease activity:5||lupus nephritis:5||Quality of life:5||mortality:5||Incidence:5||Susceptibility:5||RA:5||singlenucleotide polymorphism:5||Risk factors:4||disease activity:4||s disease:4||Osteoporosis:4||Methotrexate:4||outcome assessment:4||Breast cancer:3||Biologic DMARDs:3||mesenchymal stem cell:3||Malignancy:3||Activity:3||Protein tyrosine phosphatase nonreceptor 22:3||activity:3||autoantibodies:3||Prognosis:3||Level:3||lupus:3||cyclooxygenase2:3||Tofacitinib:3||mycophenolate mofetil:3||Dermatomyositis:3||health care:3||CD40:3||nephritis:3||network metaanalysis:3||cyclophosphamide:3||costeffectiveness analysis:3||Hepatitis B virus:3||Autoimmune disease:3||Remission:3||prevalence:3||Treatment:3||organ damage:3||Infliximab:3||Autoantibodies:3||Rheumatic disease:3||Ethnicity:3||HLAG:3||Interstitial lung disease:3||genetics:3||SNP:3||Tumor necrosis factor inhibitor:3||Autoimmunity:3||GWAS:3||ankylosing spondylitis:2||safety:2||shared epitope:2||INTERFERON REGULATORY FACTOR 5:2||antiphospholipid antibodies:2||Arthritis, Rheumatoid:2||Clinical trial:2||autoimmune disease:2||Coffee:2||tuberculin skin test:2||Gene expression:2||type I interferon:2||biological therapy:2||vasculitis:2||biosimilar:2||vitamin D:2||Inflammatory bowel disease:2||Inflammatory disease:2||Rhematoid arthritis:2||Gene frequency:2||Rheumatoid Arthritis:2||Rheumatoid arthritis (RA):2||Mortality:2||Cohort:2||Risk factor:2||Rituximab:2||Injury:2||Azotemia:2||SHARED EPITOPE:2||corticosteroid:2||B cells:2||COVID19:2||damage:2||diagnostic accuracy:2||discontinuation:2||Acute myocardial infarction:2||CRP:2||Coronary artery disease:2||Early diagnosis:2||CTLA4:2||efficacy:2||Intravascular ultrasonography:2||Genomewide association study:2||Genotype:2||etanercept:2||Spondyloarthropathies:2||AntiTNFα:2||genetic association:2||Antirheumatic agents:2||Systematic review:2||genomewide association study:2||Gout:2||glucocorticoids:2||Organ damage:2||Systemic lupus erythematosus (SLE):2||Juvenile idiopathic arthritis:2||hepatitis B virus reactivation:2||Korean:2||Cytochrome P450:2||inflammation:2||infliximab:2||Biosimilar:2||LONGTERM:2||HLADRB1:2||DAS28:2||Atherosclerosis:2||PON1:2||Latent tuberculosis:2||latent tuberculosis infection:2||Alcohol intake:2||level:2||PXK:2||HRQoL:2||Leukopenia:2||FAS:2||lymphoma:2||Cardiovascular Disease:2||mendelian randomization:2||Baricitinib:2||DMARDs:2||Death:2||BuddChiari syndrome:2||Tolllike receptor:2||Treatment Outcome:2||Tuberculosis:2||Tumor necrosis factor:2||MEDLINE:2||Celecoxib:2||outcomes research:2||Hyperuricemia:2||Ulcerative colitis:2||Behcet&apos:2||Filgotinib:2||Uric acid:2||MORTALITY:2||Uveitis:2||Polymorphisms:2||CD226:2||Polymyositis:2||Prematrure:2||Vertebral fracture assessment (VFA):2||Vitamin D:2||Vitamin D receptor:2||Discordance:2||Disease Activity:2||Chronic kidney disease:2||remission:2||Proteinuria:2||rheumatic disease:2||rheumatic diseases:2||risk factors:2||Disease activity score:2||IFN:1||IL1 beta:1||IL16:1||IL17A:1||IL18:1||IL6:1||IL6 polymorphisms:1||IL6, biologics:1||IL10:1||IRF5:1||ITGAM:1||Immune Cell Gene Expression Atlas from the University of Tokyo:1||Immune system:1||Immunoglobulin:1||Immunosuppressive agents:1||Influencing factors:1||Influenza:1||Interferon regulatory factor 5:1||Interleukin 23 (IL23):1||Interleukin 23 receptor (IL23R):1||Interleukin 23 receptor gene (IL23R gene):1||Interleukin1:1||Interleukin10:1||Interleukin18:1||Interleukin23R:1||Interleukin6:1||Isoniazid:1||JAK2/STAT3 signaling:1||Janus Kinase Inhibitor:1||Janus kinase:1||Janus kinase inhibitors:1||Japanese:1||Juvenile rheumatoid arthritis:1||KLRG1:1||KOREA:1||KSF36:1||Korean Health Assessment Questionnaire:1||Korean National Health Insurance reimbursement criteria:1||Korean validation:1||LUNG CANCER:1||LUPUS NEPHRITIS:1||LYN:1||Latent Tuberculosis Infection:1||Leflunomide:1||Leptin:1||Leptin pathway:1||Linkage disequilibrium:1||Literature review:1||Lung:1||Lupus:1||Lupus Erythematosus:1||Lupus erythematosus:1||Lupus erythematosus, Systemic:1||Lymphocytes:1||MALIGNANCY:1||MCP1:1||MERTK:1||MHC2TA:1||MIF:1||MIF level:1||MS:1||MTHFR:1||MTX toxicity:1||MYCOBACTERIUM TUBERCULOSIS:1||MYH9:1||Magnetic resonance imaging:1||Major histocompatibility complex:1||Malignancies:1||Mannosebinding lectin gene:1||Mapping:1||Matrix metalloproteinases:1||Medical care:1||Medication persistence:1||Medication practices:1||Medication therapy management:1||Mesenchymal stem cells:1||Mesenchymal stem cells (MSCs):1||Metatarsalphalangeal:1||Methylenetetrahydrofolate reductase:1||MiR146a:1||MicroRNA:1||MicroRNAs:1||Migration inhibitory factor:1||Multicenter clinical trial:1||Muscle strength:1||Myositis:1||NIH regimen:1||NLRP3:1||NSAIDs:1||Nationwide database:1||Nephritis:1||Neuropsychiatric:1||Nitration:1||Nocardia:1||Nonresponsiveness:1||Nucleosomes:1||OCCULT INFECTION:1||ORGAN DAMAGE:1||OSTEOPONTIN:1||OUTCOME ASSESSMENT:1||Obesityrelated QOL:1||Omega3 polyunsaturated fatty acids:1||Organizing pneumonia:1||Osteoarthritis:1||Osteoblastic activity and differentiation:1||Osteoporosisa:1||Outcome:1||Outcome Assessment:1||Outcome assessment:1||Outcomes:1||Overlap syndrome:1||Overweight:1||Oxygen onsumption:1||PADI4:1||PDL1:1||POLYMORPHISM:1||PROGNOSIS:1||PTPN22:1||PTPRC:1||PTPRT:1||Pain:1||Pathology:1||Pathwaybased analysis:1||Patient Care Team:1||Patient global assessment:1||Patient reported outcome measures:1||Patient reported outcomes:1||Pediatric Patient:1||Periodontitis:1||Peripheral tolerance:1||Phase 3 clinical trials:1||Physician global assessment:1||Placebo effect:1||Pneumomediastinum:1||Pneumonia:1||Podocytes:1||Poly(ADPribose) polymerase (PARP):1||Polygenic risk score:1||Polymorphism, genetic:1||Polymorphism, single nucleotide:1||Polymyalgia Rheumatica:1||PostGWAS analysis:1||Postural balance:1||Preventive Measures:1||Primary Sjogren&apos:1||Productivity loss:1||Prolactin:1||Promoter regions, genetic:1||Pulmonary tuberculosis:1||QALY:1||QuantiFERONTB Gold InTube test:1||QuantiFERONTB gold in tube test:1||RESPONSIVENESS:1||RHEUMATIC DISEASES:1||Radiation:1||Radiographic progression:1||Radiography:1||Randomized clinical trials:1||Raynaud&apos:1||Recommendation:1||Recurrent intestinal pseudoobstruction:1||Registry:1||Republic of Korea:1||Response:1||Responsiveness:1||Retention:1||Rheumatic diseases:1||Rheumatoid factor:1||Risk Factors:1||SARSCoV2:1||SEX:1||SINGLENUCLEOTIDE POLYMORPHISMS:1||SLEDAI:1||SMOKING:1||Sarilumab:1||Serine proteinase inhibitors:1||Severity of Illness:1||Side effects:1||Signs and Symptoms:1||Sleep:1||South Koreans:1||Spinal Fractures:1||Spinal fracture:1||Spinal fractures:1||Spondylitis, Ankylosing:1||Susceptibility weighted imaging:1||Synergistic interaction:1||Systemic:1||Systemic lupus:1||Systemic lupus erythematosus and autoimmunity:1||Systemic lupus erythematous:1||Systemic onset:1||Systemic sclerosis:1||Tlymphocyte subsets:1||T2T:1||TGFbeta 1:1||TLR8:1||TNF:1||TNF blockers:1||TNF��:1||TNFalpha:1||TNFalpha blockers:1||TNFblocker:1||TNFI:1||TNFR:1||TNFR pathway:1||TNFRFc Fusion Protein:1||TRAF1C5:1||TREX:1||TREX1:1||TUMOR NECROSIS FACTOR ANTAGONIST:1||TUMOR NECROSIS FACTOR BLOCKER:1||TUMOR NECROSIS FACTORalpha BLOCKER:1||TUMOR NECROSIS FACTORalpha INHIBITORS:1||TUMOR NECROSIS FACTORalpha POLYMORPHISM:1||TYK2:1||TYMS polymorphism:1||Tacrolimus:1||Tai Chi:1||Tea:1||Telomere length:1||Tolerability:1||Toxicity:1||Treattotarget:1||Tumor necrosis factor alpha inducible protein 3:1||UBCH7 expression:1||UBE2L3:1||Ulnar artery:1||Unmet need:1||Uric Acid:1||Utility:1||VEGF:1||Validation study:1||Variant alleles:1||Vasculitis:1||Vertebral fracture:1||Vertebral fracture (VF):1||Vitiligo:1||WTP:1||Water intoxication:1||White matter:1||acetaminophen:1||active:1||acutephase protein:1||adiponectin:1||adverse event:1||alphalipoic acid:1||angiogenesis:1||antiCCP antibodies:1||antibeta 2 glycoprotein IgA:1||antiphospholipid syndrome:1||antirheumatic agents:1||antitumor necrosis factor therapy:1||antitumour necrosis factor therapy:1||antioxidants:1||antirheumatic agents:1||association:1||avascular necrosis:1||bacterial infection:1||barriers to clinical care:1||biologic DMARDs:1||biologic agent:1||biologics:1||body mass index:1||bone density:1||bone erosion:1||brain mapping:1||burden of disease:1||cardiovascular disease:1||celltypespecific:1||cerebritis:1||chromatin:1||classification criteria:1||clinical manifestation:1||clinical trial design:1||cluster analysis:1||cohort studies:1||cohort study:1||combination therapy:1||complete remission:1||connective tissue disease:1||consensus:1||contraception:1||core set:1||costbenefit analysis:1||cumulative corticosteroid:1||cytokines:1||deficiency:1||development:1||disability:1||disease state:1||disease susceptibility:1||diseasemodifying antirheumatic drugs (biologic):1||doublebound dichotomous choice:1||drug development:1||educational attainment:1||efferocytosis:1||epistatic interaction:1||erosion:1||erythematosus:1||estrogen:1||ethnicity:1||femur:1||functional polymorphism:1||genetic heterogeneity:1||genetic risk score:1||genotypephenotype association:1||haematological disorder:1||haplotypes:1||health services research:1||healthrelated quality of life:1||healthcare:1||hepatitis B virus occult carrier:1||heterogeneity:1||histiocytic necrotizing lymphadenitis:1||hydroxychloroquine:1||hyponatraemia:1||immune cell:1||immunogenetics:1||immunosuppressant:1||inception cohort:1||interferon:1||interferongamma release assay:1||interferongamma release assays:1||interleukin4:1||interstitial lung disease:1||irritable bowel syndrome:1||juvenile idiopathic arthritis:1||juvenile systemic lupus erythematosus:1||kidney infiltration:1||lateonset:1||leucopenia:1||linkage disequilibrium (LD):1||longterm followup:1||lung ultrasound:1||lupus low disease activity state:1||lymphadenopathy:1||memory disorders:1||methotrexate:1||methylenetetrahydrofolate reductase:1||microsatellite typing:1||morbidity:1||multiethnic association study:1||multiethnic association study:1||multitarget therapy:1||n3 polyunsaturated fatty acids:1||neurological:1||nonsteroidal:1||normal:1||opportunistic infections:1||organ involvement:1||osteoarthritis:1||osteonecrosis:1||osteonecrosis of the femoral head (ONFH):1||osteoporosis:1||outcome:1||p21:1||p53:1||pathogenesis:1||pathwaybased analysis:1||patient access:1||patientreported outcomes:1||pharmacoeconomics:1||phorbol ester:1||poly(ADPribose) polymerases:1||predictor:1||procalcitonin:1||progesterone:1||prognosis:1||prospective study:1||psoriasis:1||psychiatric:1||pulmonary hypertension:1||quality of life:1||qualityadjusted life years:1||quercetin:1||radiographic progression:1||randomized controlled trial:1||receptor:1||renal lupus:1||response to therapy:1||reversible cerebral vasoconstriction syndrome:1||rheumatoid arthritis:1||risk:1||rituximab:1||s phenomenon:1||s syndrome:1||sharp score:1||single nucleotide polymorphism:1||singlephoton emission computed tomography:1||skin:1||smoking:1||subarachnoid hemorrhage:1||systemic lupus erythematous:1||tacrolimus:1||tactolimus:1||therapeutic response:1||therapeutics:1||threshold:1||toxicity:1||tramadol:1||transcriptome:1||triple therapy:1||tuberculin skin tests:1||tuberculosis:1||tumor necrosis factor inhibitor:1||vascular endothelial growth factor (VEGF):1||vertebral fracture:1||visfatin:1||vitiligo:1||waf1:1||골관절염:1||관상동맥 질환:1||균형감:1||근력:1||단백뇨:1||동맥경화:1||류마티스관절염:1||만성콩팥병:1||심폐기능:1||전신홍반루푸스:1||질소혈증:1||타이치:1||2010 ACR/EULAR Classification Criteria:1||혈관내 초음파:1||ABCG2:1||ADMINISTRATIVE CLAIMS:1||AMERICAN COLLEGE OF RHEUMATOLOGY:1||ANA:1||ANKYLOSING SPONDYLITIS:1||ANTICITRULLINATED PROTEIN AUTOANTIBODIES:1||APOL1:1||ATIC:1||Adalimumab:1||Adult onset Still&apos:1||Age:1||Algorithm:1||Alzheimer&apos:1||Angiotensinconverting enzyme:1||AntiCCP antibody:1||AntiP. gingivalis antibody:1||AntiRA33 antibody:1||AntiSa antibody:1||AntiTNF drugs:1||Anticitrullinated protein antibodies:1||AntidsDNA antibodies:1||Antiinflammatory agents:1||Antitumor necrosis factor alpha therapy:1||Antinuclear antibodies:1||Apoptosis:1||Arteriography:1||Arthritis, rheumatoid:1||Asia:1||Asia Pacific region:1||AsiaPacific:1||Associated factors:1||Autoantigens:1||Autoimmune Diseases:1||Avascular necrosis:1||B cell:1||Blymphocytes:1||BANK1:1||BASDAI:1||BCR:1||BIOLOGICS:1||BIOMARKERS:1||BMI:1||Bayesian network metaanalysis:1||Biochemical marker:1||Bioinformatic analysis:1||Biologic DiseaseModifying Antirheumatic Drugs:1||Biologic agent:1||Biological marker:1||Biological markers:1||Biological therapies:1||Biological therapy:1||Biologics:1||Biomarker:1||Biomarkers:1||Bone Mineral Density:1||Bone Scintigraphy:1||Bone turnover:1||Brachydactyly:1||Creactive protein:1||CCR5Delta 32 polymorphism:1||CD24:1||CD8 Tcell:1||CDKN1A:1||CHILDHOOD ONSET:1||CLASSIFICATION CRITERIA:1||CLINICAL FEATURE:1||COHORT STUDIES:1||COMPLEMENTARY AND ALTERNATIVE MEDICINE:1||COVID19 Pandemic:1||CXCL10:1||CXCR3:1||CYCLOPHOSPHAMIDE:1||CYP1A2:1||CYP2D6:1||Calprotectin:1||Cancer:1||Cardiovascular disease:1||Casecontrol:1||Casecontrol studies:1||Causal association:1||Cerebral microbleeds:1||Certolizumab:1||Childbearing Decisions:1||Chondroitin:1||Chronic kidney failure:1||Claims data:1||Clinical Effectiveness:1||Clinical characteristics:1||Cohort studies:1||Comorbidity:1||Complement system proteins:1||Connective tissue diseases:1||Copy number variation:1||Copy number variations:1||Correlation:1||Corticosteroids:1||Cost effectiveness:1||Cost of illness:1||Cytokine:1||DEPRESSION:1||DFS70:1||DISEASE ACTIVITY:1||DISEASE PROGRESSION:1||DMARD:1||DNase IV:1||Deficiency:1||Dermatomyositis/polymyositis:1||Diagnostic accuracy:1||Diagnostic imaging:1||Direct costs:1||Disability assessment:1||Discontinuation:1||Disease Activity Score:1||Disease activity index:1||Disease susceptibility:1||Diseasemodifying antirheumatic drugs:1||Diseasemodifying, antirheumatic drugs:1||Drug efficacy:1||Drug persistency:1||Drug retention rate:1||Drug side effects:1||Drug therapy:1||Drug utilization:1||Drugsrelated side effects and adverse reactions:1||EFFICACY SAFETY:1||EQ5D:1||ESR:1||Effectiveness:1||Elderly:1||Endothelial nitric oxide synthase:1||Enrollment:1||Epistasis:1||Ethnic groups:1||Etiology:1||EuroQol (EQ5D):1||EuroQol EQ5D:1||Euroregimen:1||Evidencebased medicine:1||FCG receptor:1||FCGR polymorphism:1||FCGR3A:1||FCGR3B:1||FOXP3:1||FRACTURE:1||Factors:1||Family Size:1||Fatigue:1||Fibrosis:1||Finemapping:1||Five dimensions:1||Follicular helper T (Tfh) cells:1||Fracture:1||Fractures:1||Frequency:1||GENETIC STUDIES:1||GLUCOCORTICOIDS:1||GOLIMUMAB:1||GSTM1:1||GSTP1:1||Gastrointestinal diseases:1||Gender:1||Gene Polymorphism:1||Gene polymorphism:1||Gene polymorphisms:1||Genegene interaction:1||Genetic association studies:1||Genetic polymorphism:1||Genetic predisposition to disease:1||Genetic risk score:1||Genetic variant:1||Genetics:1||Genomewide association studies:1||Glucocorticoids:1||Glucosamine:1||Golimumab:1||Granulomatous process.:1||Guideline:1||HAQ:1||HAQDI:1||HEPATITIS B VIRUS:1||HLA antigens:1||HLAB27 antigen:1||HLADRB1*09:01:1||HLADRBI:1||HOUSEHOLD:1||HOXD gene:1||Health Assessment Questionaire:1||Health Assessment Questionnaire (HAQ):1||Health Care:1||Health assessment questionaire:1||Health outcomes assessments:1||Health services research:1||Healthrelated quality of life:1||Hemorrhage:1||Histopathology:1||Hormone receptors, nuclear:1||Hyponatremia:1||Hypouricemia:1||ICAM1:1||

STATISTICS: Total View :4,970,644; Today View :1,528

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE